FDA Understaffed? More Delays Every Month (BCRX, MAPP, OGXI, OXGN)

So we have noticed the FDA has been missing more and more dates so far this year. One reasons I saw for the FDA missing a date was due to “staffing issues”. Is the FDA now understaffed? The FDA is normally really good at meeting their Prescription Drug User Fee Act (“PDUFA“) dates but in some rare cases they are delayed and there is no telling when the decision will come.

In the biotech world, FDA decisions can be a gamble but statistics are on your side. 70%-90% of all drugs in Phase 3 testing receive FDA approval. The reason why so many drugs are approved at that point is because most the unsuccessful ones are weeded out in the Phase 1, 2, and 3 trials.

We will help you find the next big biotech stock pending FDA approval, we are for a limited time we extended our offer and are giving away a FREE FDA Calendar to the next 2,000 new forum members of the FavStock.com stock forums. Exclusively for our Stock Market Forum members, don’t miss out. Other sites charge you $120 or more for an FDA Calendar, we give it to you for FREE!

We have seen what can happen when these volatile FDA stocks and with FDA decisions. Just take a look at BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX),MAP Pharmaceuticals Inc. (NASDAQ:MAPP), OncoGenex Pharmaceuticals Inc(NASDAQ:OGXI), and OXiGENE, Inc. (NASDAQ:OXGN)

Stop by FavStocks.com and get your FREE FDA Calendar now! We have two companies on the calendar this week alone!

Free FDA Calendar